<DOC>
	<DOCNO>NCT01104493</DOCNO>
	<brief_summary>To assess safety new influenza virus vaccine contain new virus strain healthy patient prior release vaccine .</brief_summary>
	<brief_title>A Clinical Study Assess Safety New Influenza Vaccine</brief_title>
	<detailed_description>This prospective , randomize , double-blind , placebo-controlled release study enroll approximately 300 healthy adult 18-49 year age . Eligible subject randomly assign 4:1 fashion receive single dose monovalent vaccine placebo intranasal spray . This study conduct multiple site United States . Randomization stratify site . Each subject receive one dose investigational product Study Day 1 . The duration study participation subject time receipt investigational product 180 day receipt investigational product . To summarize primary safety phase data ( Study Days 1-8 ) , study unblinded analysis team MedImmune data least Study Day 8 lock .</detailed_description>
	<criteria>Male female , 18 49 year age ( yet reach 50th birthday ) time investigational product administration Healthy medical history physical examination Written inform consent locally require authorization ( eg , Health Insurance Portability Accountability Act United States America , European Union [ EU ] Data Privacy Directive EU ) obtain subject/legal representative prior performing protocolrelated procedure , include screen evaluation Female subject childbearing potential , ( ie , unless least 2 year postmenopausal , surgically sterile [ eg , bilateral tubal ligation , bilateral oophorectomy , hysterectomy ] , sterile male partner , practice abstinence ) must use effective method avoid pregnancy ( include oral , transdermal , implanted contraceptive , intrauterine device , female condom spermicide , diaphragm spermicide , cervical cap , use condom spermicide sexual partner ) 30 day prior administration investigational product , must agree continue use precaution 60 day investigational product administration . In addition , subject must also negative urine blood pregnancy test screening , screen Day 1 occur day , day vaccination prior randomization . Males , unless surgically sterile must use effective method birth control female partner must agree continue use contraceptive precaution least 30 day dose investigational product ( Study Day 1 Study Day 31 ) Subject available telephone Ability understand comply requirement protocol , judge investigator Ability complete followup period 180 day dose required protocol History hypersensitivity component vaccine , include egg egg protein serious , life threatening , severe reaction previous influenza vaccination History hypersensitivity gentamicin Any condition inactivate influenza vaccine indicate , include chronic disorder pulmonary cardiovascular system ( eg , asthma ) , chronic metabolic disease ( eg , diabetes mellitus ) , renal dysfunction , hemoglobinopathy require regular medical followup hospitalization precede year Note : A history asthma require regular medical followup hospitalization precede 2 year exclusionary . Investigator judgment require determine whether subject history asthma ; however , adult subject , remote history wheeze remote diagnosis asthma investigator consider relevant current health need consider history asthma . For example , childhood asthma require treatment adulthood necessarily exclusionary Acute febrile ( &gt; 100.0°F oral equivalent ) and/or clinically significant respiratory illness ( eg , cough sore throat ) within 14 day prior randomization Any known immunosuppressive condition immune deficiency disease , include human immunodeficiency virus ( HIV ) infection , ongoing immunosuppressive therapy History GuillainBarré syndrome A household contact severely immunocompromised ( eg , hematopoietic stem cell transplant recipient , period immunocompromised individual require care protective environment ) ; additionally , subject avoid close contact severely immunocompromised individual least 21 day receipt investigational product Receipt investigational agent within 30 day prior randomization , expect receipt 30 day dose investigational product Receipt nonstudy vaccine within 30 day prior randomization , expect receipt 30 day receipt investigational product Expected receipt antipyretic analgesic medication daily every day basis randomization 14 day receipt investigational product Note : A daily dose 81 mg aspirin prophylactic use consider contraindication enrollment . Administration intranasal medication within 14 day prior randomization , expect receipt 14 day administration investigational product Receipt influenza antiviral therapy antiviral agent within 48 hour prior investigational product administration expect receipt influenza antiviral therapy antiviral agent 14 day receipt dose investigational product Known suspect mitochondrial encephalomyopathy Nursing mother Any condition ( eg , chronic cough ) , opinion investigator , would interfere evaluation investigational product interpretation subject safety study result Employees clinical study site , individual involve conduct study , immediate family member individual</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>